Nolasco-Quiroga M, Alfaro-Hernández L, Godínez-Aguilar R, Flores-García O, Juárez-Islas AP, Salas-Cuevas G, Olvera-Serrano Á, Palacio-Reyes C, Rosas-Díaz C

Language: Spanish
References: 14
Page: 15-22
PDF size: 2044.96 Kb.

ABSTRACT

Introduction: In December 2019 in Wuhan, China, a new coronavirus, SARS-CoV-2, was identified, which spread worldwide. In Mexico, epidemiological and experimental research has been limited. Given the economic, social, and ethnic diversity of the 32 Mexican states, it becomes crucial to analyze the behavior of the COVID-19 pandemic in the different states. Objective: the main objective of this study was to analyze the frequencies of positive cases and the lethality associated with COVID-19 in the different states of Mexico, to identify those states with the highest case fatality rates. Material and methods: for this study, the open database of the General Directorate of Epidemiology of Mexico was used, from March 2020 to September 2023. Positive cases diagnosed by PCR, antigens, clinical opinion or epidemiological association were analyzed. Case fatality rates were calculated at the national and state levels, and a hierarchical clustering analysis was performed. Results: from 2020 to September 2023, 6’338,991 positive cases and 326,261 deaths were registered nationwide (lethality rate of 5%). The monthly national case fatality rate at the beginning of 2020 was high at approximately 12%, gradually decreasing to 5%. Heterogeneity in lethality was observed among the two states of the republic, with ranges from more than 20%. The cluster analysis identified states with low, medium and high lethality. No significant differences were found in most comorbidities between the lethality groups, although there were significant differences in ambulatory condition and hypertension. Conclusions: heterogeneity in the lethality of COVID-19 was observed among the states of Mexico, with states such as. Outpatient status and prevalence of hypertension may have played a role in regional disparities, among other factors that were not analyzed in this study.

REFERENCES

1. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al.Identification of a novel coronavirus causing severepneumonia in human: a descriptive study. Chin Med J (Engl).

2. 2020;133(9):1015-1024. doi: 10.1097/CM9.0000000000000722.

3. Hui DS, Azhar EE, Madani TA, Ntoumi F, Kock R, Dar O, et al. Thecontinuing 2019-nCoV epidemic threat of novel coronavirusesto global health - The latest 2019 novel coronavirus outbreakin Wuhan, China. Int. J. Infect. Dis. 2020;91:264-266.

4. Escudero X, Guarner J, Galindo-Fraga A, Escudero-SalamancaM, Alcocer-Gamba MA, Del-Río C. The SARS-CoV-2 (COVID-19)coronavirus pandemic: current situation and implications forMexico. Arch Cardiol Mex. 2020;90(Supl):7-14. doi: 10.24875/ACM.M20000064

5. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimatingthe asymptomatic proportion of coronavirus disease 2019(COVID-19) cases on board the Diamond Princess cruise ship,Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180.doi: 10.2807/1560-7917.ES.2020.25.10.2000180.

6. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, MartinezR, Bernstein K, et al. Coronavirus disease 2019 infection amongasymptomatic and symptomatic pregnant women: two weeksof confirmed presentations to an affiliated pair of New YorkCity hospitals. Am J Obstet Gynecol MFM, 2020;2(2):100118.doi: 10.1016/j.ajogmf.2020.100118.

7. Gao W, Lv J, Pang Y, Li LM. Role of asymptomatic andpre-symptomatic infections in covid-19 pandemic. BMJ.2021;375:n2342. doi: 10.1136/bmj.n2342.

8. Li Z, Guan X, Mao N, Luo H, Qin Y, He N, et al. Antibodyseroprevalence in the epicenter Wuhan, Hubei, and sixselected provinces after containment of the first epidemicwave of COVID-19 in China. Lancet Reg Health West Pac.2021;8:100094. doi: 10.1016/j.lanwpc.2021.100094.

9. Wu Z, McGoogan JM. Characteristics of and important lessonsfrom the Coronavirus Disease 2019 (COVID-19) outbreakin China: summary of a report of 72,314 cases from theChinese Center for Disease Control and Prevention. JAMA.2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648.

10. Yang R, Gui X, Xiong Y. Comparison of clinical characteristics ofpatients with asymptomatic vs symptomatic Coronavirus disease2019 in Wuhan, China. JAMA Netw Open. 2020;3(5):e2010182.doi: 10.1001/jamanetworkopen.2020.10182.

11. Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-AlanocaA, Alarcón-De-La-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, et al. Lancovid Clinical features of the firstcases and a cluster of Coronavirus Disease 2019 (COVID-19)in Bolivia imported from Italy and Spain. Travel Med InfectDis. 2020;35:101653.

12. López-Alonso M, Vélez-Grajales R. Height and inequality inpost-1950 Mexico: a history of stunted growth. Rev Hist Econ/JIber Lat Am Econ Hist. 2019;37(2):271-296.

13. Mendez-Dominguez N, Alvarez-Baeza A, Carrillo G.Demographic and health indicators in correlation to interstatevariability of incidence, confirmation, hospitalization, andlethality in Mexico: preliminary analysis from imported andcommunity acquired cases during COVID-19 outbreak. Int JEnviron Res Public Health. 2020;17(12):4281. doi: 10.3390/ijerph17124281.

14. Suárez V, Suarez-Quezada M, Oros-Ruiz S, Ronquillo-De JesúsE. Epidemiología de COVID-19 en México: del 27 de febreroal 30 de abril de 2020. Rev Clin Esp. 2020;220(8):463-471. doi:10.1016/j.rce.2020.05.007.